Peptide vaccines mainly target leukemia-associated antigens including nephroblastoma 1 (WT1), protease 3 (PR3), hyaluronic acid-mediated motor receptor (RHAMM), and mucin 1 (MUC1) (134). This evidence concerns the gene MUC1 and leukemia.